FindTrial
Sign In

intradermal,intramuscular

2 trials

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Faculty of Medicine Siriraj hospital, Mahidol University

Conditions

Intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2 booster vaccine, third dose, SAR-CoV2, older adultThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2. booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, Thailand

Phase 4

Intradermal booster COVID-19 vaccination
RecruitingTCTR20220112002
Faculty of Medicine Siriraj Hospital, Mahidol UniversityIntradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2 booster vaccine, third dose, SAR-CoV2, older adult
Start: 2022-01-09Target: 210Updated: 2026-08-03
Intradermal second booster COVID-19 vaccination
Active, not recruitingTCTR20230411008
Faculty of Medicine Siriraj hospital, Mahidol UniversityThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2. booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, Thailand
Start: 2022-05-08Target: 210Updated: 2026-08-03

Related Papers

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
The journal of nutrition health & aging2024-07-172 citations
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
The Journal of Infectious Diseases2023-05-048 citations